Clinical Trial Update: Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a combination therapy of HAIC, sintilimab, and bevacizumab for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• HAIC (hepatic artery infusion chemotherapy)
• Sintilimab (sintilimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN